KMT2D and plasma cell myeloma: Our mutation profile (ARID1A, KMT2D, BCL7A, PTPN11, NUP214) and high CNV load converge with patterns reported across extramedullary/myeloma cohorts, notably MAPK pathway lesions and 1q amplifications.